Nanjing Frontier Acquires Rights to Rockefeller University HIV/AIDS Antibody

Nanjing Frontier Biotechnologies acquired global rights to a novel broad-spectrum HIV neutralizing antibody from The Rockefeller University of the US. Frontier will combine the antibody with albuvirtide, its own long-acting anti-HIV/AIDS peptide, to treat and prevent HIV infection and AIDS. In 2016, Nanjing filed an NDA for albuvirtide with the CFDA, the world's first NDA for a long-acting HIV medicine. Financial details of the agreement between Frontier and Rockefeller University were not disclosed. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.